

Oslo companies and institutes invited to attend the BaSIC Oslo Road Show 13 April 2011-03-10

GE and Applied Biosystems, using Oslo as a testbed for new technologies and ideas.

GlaxoSmithKline, AstraZeneca, MSD, Roche and Pfizer (Norwegian subsidiaries)

SINTEF, the Nordic countries' largest independent applied research organization
(<http://www.sintef.no/Home/Technology-and-Society/>)

Radium Cancer Hospital, which has spun out a multitude of cancer-related companies such as Dynal, Algeta, GemVax and PhotoCure. (<http://www.ous-research.no/institute/>)

Oslo University Hospital, one of the largest in Europe: (<http://www.oslo-universitetssykehus.no/omoss/english/Sider/side.aspx>)

Akershus University Hospital, one of the most technologically advanced in Europe:
(http://www.ahus.no/modules/module_123/proxy.asp?D=2&C=1079&I=17136)

Tandberg, known for its video conference systems, recently purchased by Cisco Systems.
(<http://www.tandberg.com/>)

Telenor, Norway's largest ICT-company, with head office located at Fornebu, just outside Oslo. Telenor is emerging as one of the fastest growing providers of mobile communications services worldwide. In 2007, Telenor ranked as the 7th largest mobile operator in the world. The Telenor Group was ranked the best Mobile Telecom company in the world by the Sustainability Yearbook 2008. (www.telenor.com)

The Department of Informatics at the University of Oslo. Together with the Norwegian Computing Center and SINTEF, the Department of Informatics provides Norway with an important research environment for ICT. (<http://www.ifi.uio.no/english/>)

PhotoCure

Focusing on oncology and dermatology markets, Oslo-based Photocure develops and sells drugs and devices based on its photodynamic therapy. This uses a locally applied photosensitizer that is activated using Photocure's proprietary light source. Photocure is developing light-activated therapeutics in late stage clinical trials for the treatment of cervical cancer and acne, and for the improvement of the appearance of the skin, as well as a diagnostic for the diagnosis of colon cancer. Photocure's lead product, Hexvix, a bladder cancer diagnostic, is approved for marketing in the EU.
(www.photocure.com)

Algeta

Oslo company Algeta is developing radiotherapeutics for an area of unmet medical need – cancers that have metastasised to bone – as well as for disseminated tumours. The targeted alpha-emitting agents are based on radium-223 and thorium-227. Alpha emitters produce short-range, densely ionising radiation that can destroy cancer cells with minimal damage to normal tissue, and are well tolerated. Alpharadin, the company's lead therapeutic, is targeted to bone and is in a phase III trial for bone metastases in hormone-refractory prostate cancer. It is also in clinical trials for bone metastases in breast cancer.
(www.algeta.com)

Clavis Pharma

Clavis Pharma uses its Lipid Vector Technology (LVT) chemistry to link lipids to existing anticancer drugs to create new chemical entities, enhancing the efficacy and safety, improving dosing schedules, creating new indications and potentially allowing oral, transdermal and inhaled administration. The Oslo-based company's lead, elacytarabine (an LVT derivative of cytarabine), is approaching phase III trials for the treatment of acute myeloid leukemia. Also in clinical development, the company is developing CP-4126 based on gemcitabine for the treatment of pancreatic cancer.

(www.clavispharma.com)

PCI Biotech

PCI Biotech began in 2000 as a subsidiary of Photocure and demerged from its parent company in 2008 and is listed on the Oslo Stock Exchange, one of only a very few biotech IPOs that year. PCI Biotech uses light technology to allow lower-dose administration of existing, effective, but highly toxic drugs. The light-directed drug delivery technology, using the company's proprietary photosensitizer Amphonex, triggers the release of biologically-active therapeutics at the disease site. The company has carried out a phase I/II trial of Amphonex with bleomycin in head and neck cancer, and is conducting preclinical studies of its photosensitizer technology in bladder cancer.

(www.pcibiotech.no)

DiaGenic

DiaGenic, based in Oslo, is developing in vitro diagnostic tests based on the identification of disease-specific peripheral gene expression signatures from biological samples including blood. DiaGenic has received marketing approval for ADtect (early detection of Alzheimer's disease) and BCtect (early detection of breast cancer) in Europe. In its pipeline, DiaGenic has projects based on gene expression signatures for Parkinson's Disease and mild cognitive impairment, a precursor to Alzheimer's disease, and is working with a major pharmaceutical company on early disease detection for clinical trials.

(www.diagenic.com)

Bionor Pharma

Bionor Pharma is in the vanguard of international biotechs developing peptide-based therapeutic vaccines for infectious diseases and cancer. Located in Oslo, the company's lead product VACC-4X for HIV is currently in Phase IIA trials, which have demonstrated that patients' CD4 counts are raised and viral loads reduced. One major benefit of the vaccine is that patients are able to enjoy a drug-free of up to 18 months, which gives their immune systems time to recover and significantly improves quality of life. Other indications for Bionor's platform include influenza, HCV and HPV.

(www.bionorimmuno.com)

Affitech

Affitech is a leading antibody therapeutics company developing products based on fully human antibodies. Founded by German and Norwegian scientists, the company merged with Danish listed company Pharmexa in 2009 followed rapidly by major Research and Development Collaboration and Licensing Agreement with the Russian biotechnology company NTS Plus. The collaboration focuses on two potential therapeutic antibody products: AT001 (also known as r84), a novel, patented therapeutic antibody to vascular endothelial growth factor (VEGF) which is being developed as a potential competitor to bevacizumab (Avastin®) for the treatment of certain human cancers. AT008, a novel, patented therapeutic antibody directed against CCR4, an important G-protein coupled receptor ("GPCR") on the surface of many cancer cells and cells of the immune system. AT008 is expected to have clinical application in the treatment of cancer and certain other diseases.

(www.affitech.com)

Santosolve

SantoSolve develops topical analgesic products based on strontium as the active agent. The Company's lead product, 2PX, is a low viscosity fluid administered topically at the site of pain. Preclinical and clinical studies have shown the product to have an excellent safety profile and strong analgesic effects in both nociceptive and neuropathic pain conditions. In 2009 the Company advanced 2PX into pivotal Phase III trials in both osteoarthritis of the knee and in chronic post-amputation pain. Both trials are expected to report results during 2010, and planning for confirmatory phase III trials are underway. The Company expects to be able to file an NDA during 2012.

(www.santosolve.com)

BerGenBio

Based and the name suggests in Bergen, BerGenBio offers contract research and development services to pharmaceutical and biotechnology companies as well as seeking collaborations for pipeline development of novel drug targets and therapeutics, including small molecules, antibodies and RNAi drugs. Typical CRO Services include single or multiple simultaneous target validation studies. These either originate with client provided target sequences or shRNAs determined using the company's proprietary CellSelectRNAi platform technology. In addition, their role in disease state determined using proprietary in vitro models. In vivo models can be TET regulated and the progression of the disease can be visualized in real time using CellSelectImaging Technology. Clients can utilize BerGenBio's cell lines and assay systems or they can provide tailored cell lines and disease modeling systems. Following target validation, compound and therapeutic screening services are offered to fast track lead compound selection for pre clinical development.

(www.bergenbio.com)